[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Medigen Biotechnology Corp (3176) - Financial and Strategic SWOT Analysis Review

November 2021 | 35 pages | ID: M85A56239ECEN
GlobalData

US$ 125.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Medigen Biotechnology Corp (3176) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Medigen Biotechnology Corp (MBC) is a pharmaceutical company that carries out the research and development of biopharmaceuticals for the treatment of liver diseases and cancers. It focuses at developing new therapeutics, principally in the area of cancer and liver diseases. The company’s product portfolio includes monoclonal antibodies; vaccines; molecular diagnostics and generic drugs. MBC also provides original equipment manufacturing (OEM) and original design manufacturing (ODM) manufacturing services in various dosage forms including orals, externals, ophthalmic and hormones; nutrition supplements; cosmeceutical products. The company’s subsidiaries include Medigen Vaccine Biologics; TBG Biotechnology Corp; and Winston Medical Supply Co., Ltd. MBC is headquartered in Taipei city, Taiwan.

Medigen Biotechnology Corp Key Recent Developments

Jul 24,2020: Dynavax and Medigen partner to develop adjuvanted Covid-19 vaccine

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Medigen Biotechnology Corp - Key Facts
Medigen Biotechnology Corp - Key Employees
Medigen Biotechnology Corp - Key Employee Biographies
Medigen Biotechnology Corp - Major Products and Services
Medigen Biotechnology Corp - History
Medigen Biotechnology Corp - Company Statement
Medigen Biotechnology Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Medigen Biotechnology Corp - Business Description
Medigen Biotechnology Corp - SWOT Analysis
SWOT Analysis - Overview
Medigen Biotechnology Corp - Strengths
Medigen Biotechnology Corp - Weaknesses
Medigen Biotechnology Corp - Opportunities
Medigen Biotechnology Corp - Threats
Medigen Biotechnology Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Medigen Biotechnology Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 24, 2020: Dynavax and Medigen partner to develop adjuvanted Covid-19 vaccine

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Medigen Biotechnology Corp, Key Facts
Medigen Biotechnology Corp, Key Employees
Medigen Biotechnology Corp, Key Employee Biographies
Medigen Biotechnology Corp, Major Products and Services
Medigen Biotechnology Corp, History
Medigen Biotechnology Corp, Other Locations
Medigen Biotechnology Corp, Subsidiaries
Medigen Biotechnology Corp, Key Competitors
Medigen Biotechnology Corp, Ratios based on current share price
Medigen Biotechnology Corp, Annual Ratios
Medigen Biotechnology Corp, Annual Ratios (Cont...1)
Medigen Biotechnology Corp, Annual Ratios (Cont...2)
Medigen Biotechnology Corp, Interim Ratios
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Medigen Biotechnology Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Medigen Biotechnology Corp, Performance Chart (2016 - 2020)
Medigen Biotechnology Corp, Ratio Charts
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Medigen Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021


More Publications